Atezolizumab (MPDL3280A) is a humanized monoclonal IgG1 antibody selectively targeting programmed death ligand 1 (PD-L1). This antibody is utilized extensively in oncological research to investigate the modulation of the immune system's response against cancer cells. Atezolizumab's specificity for PD-L1 aids in the study of immune checkpoint pathways, potentially leading to new therapeutic strategies in cancer treatment.
Atezolizumab (MPDL3280A) is a humanized monoclonal IgG1 antibody selectively targeting programmed death ligand 1 (PD-L1). This antibody is utilized extensively in oncological research to investigate the modulation of the immune system's response against cancer cells. Atezolizumab's specificity for PD-L1 aids in the study of immune checkpoint pathways, potentially leading to new therapeutic strategies in cancer treatment.
Targets
hPD-L1(Cell-free assay) 0.4 nM(Kd)
Product Information
Catalog Num
AT0244
Molecular Weight
144600
CAS Number
1380723-44-3
Isotype
Human IgG1 (N297A) kappa, Isotype Control
Species
Humanized
Synonyms
MPDL3280A
Storage
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
